ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Part of paid clinical trials in East Windsor, New Jersey.

Sponsor
Psoriasis Treatment Center of Central New Jersey
Study ID
NCT04347473
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ilumya Injectable Product — DRUG
    IL-23 injection

Study Details

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Key Dates

Start date
Apr 6, 2020
Status verified
Apr 2020
Primary completion
Dec 30, 2020
Completion
Mar 1, 2021

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ilumya
    Ilumya 100mg subcutaneous at weeks 0, 4 and 16.

Primary Outcome Measure

Body surface area [ Time Frame: 16 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Psoriasis Treatment Center of Central New JerseyEast WindsorNew Jersey08520
Elise Nelson
[email protected]
609-443-4500
Jerry Bagel, MD (PRINCIPAL_INVESTIGATOR)
David Nieves, MD (SUB_INVESTIGATOR)
Alexa Hetzel, PA-C (SUB_INVESTIGATOR)
Brianna Butler, PA-C (SUB_INVESTIGATOR)
Wendy Myers, MD (SUB_INVESTIGATOR)

Find similar trials in East Windsor, NJ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Psoriasis Treatment Center of Central New Jersey· East Windsor, NJ

Related Studies